Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HAIC Synchronously Combined With Bevacizumab and Toripalimab First-line for Advanced Hepatocellular Carcinama

NCT04627363 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04627363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04627363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HAIC Synchronously Combined With Bevacizumab and Toripalimab First-line for Advanced Hepatocellular Carcinama
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2021
Completion date
June 30, 2023
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, hepatocellular carcinoma, liver neoplasms, oxaliplatin, toripalimab